GlassScriptPhysician profile
Catherine L Farinet
NPI 1801821723
$2,027.92
in general payments reported to CMS, 2019-2025
36 companies · $621 in 2025
The $621 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $89.81 · 2021: $71.08 · 2022: $73.20 · 2023: $303 · 2024: $607 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.32 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.85 | 2021-2025 | |
| Novo Nordisk INC | $281.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $124.23 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $109.31 | 2019-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $87.76 | 2019-2024 | Delstrigo, Pifeltro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.84 | 2023-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $58.13 | 2022-2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $51.37 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $50.22 | 2024-2025 | |
| Viiv Healthcare Company | $49.42 | 2024-2025 | Apretude |
| Glaxosmithkline, LLC. | $44.12 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $41.99 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $41.04 | 2025 | |
| Exact Sciences Corporation | $35.98 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $35.31 | 2025 | Austedo Xr, Uzedy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.13 | 2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $32.15 | 2023-2024 | |
| Grifols USA, LLC | $28.82 | 2020 | |
| Intuitive Surgical, INC. | $28.28 | 2024 | |
| Axsome Therapeutics, INC. | $27.35 | 2024 | Auvelity |
| Inspire Medical Systems, INC. | $27.16 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $20.89 | 2021 | |
| Amarin Pharma, INC. | $20.54 | 2020 | |
| Astellas Pharma US INC | $20.21 | 2019 | |
| Emd Serono, INC. | $19.90 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.18 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.12 | 2025 | Caplyta |
| Amgen INC. | $18.52 | 2019 | |
| Cipher Pharmaceuticals US LLC | $17.98 | 2025 | Spinosad, Natroba |
| Lundbeck LLC | $17.75 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.13 | 2023 | Jardiance |
| Indivior INC. | $15.60 | 2024 | Perseris |
| Phathom Pharmaceuticals, INC. | $14.43 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $14.42 | 2024 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $13.68 | 2019 | |
| Theratechnologies INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Farinet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.